CNBC
•87% Informative
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago .
The company recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as said sales slumped in its multiple sclerosis therapies.
The results come amid the rollout of Biogen and Eisai 's Leqembi , the first drug found to slow the progression of Alzheimer's to win FDA approval.
Biogen issued full-year 2024 guidance that calls for adjusted earnings of $15 to $16 per share.
Skyclarys from Biogen 's acquisition of Reata Pharmaceuticals in July brought in $56 million in fourth-quarter revenue.
EU regulators approved the drug on Monday for Friedreich ataxia in patients ages 16 and up.
The companies are also working toward approval of an injectable version of Leqembi , which showed promising results in a clinical trial in October .
VR Score
92
Informative language
96
Neutral language
37
Article tone
formal
Language
English
Language complexity
50
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
3
Affiliate links
no affiliate links